-
Tigermed Announces Acquisition of Majority Stake in Shanghai Guanhe Pharmaceutical for CNY 140 Million
•
Tigermed (SHE: 300347, HKG: 3347) has announced its intention to acquire a 40.5650% stake in Shanghai Guanhe Pharmaceutical Co., Ltd (hereinafter referred to as “Guanhe Pharmaceutical”) from DiAn Diagnostics (SHE: 300244) and Suzhou Yingkai Xinyun Enterprise Management Consulting Co., Ltd (hereinafter referred to as “Suzhou Yingkai”, a subsidiary of DiAn…
-
Tigermed Partners with Beijing Government to Open North Headquarters, Expanding Collaboration in Biotech
•
Tigermed, a prominent Contract Research Organization (CRO) with a presence in both Shenzhen (SHE: 300347) and Hong Kong (HKG: 3347) stock exchanges, has forged a strategic partnership with the Beijing government. This collaboration is marked by the inauguration of the company’s North Headquarters in the capital city. Under this partnership,…
-
Tigermed Expands Asia Pacific Presence with Acquisition of Japanese CRO Medical Edge
•
Tigermed (SHE: 300347, HKG: 3347), a leading China-based Contract Research Organization (CRO), has announced the acquisition of Medical Edge Co., Ltd, a Japan-headquartered CRO. With this strategic move, Medical Edge will become a wholly-owned subsidiary of Tigermed, enhancing the company’s ability to provide high-quality mathematical statistics and electronic data solutions…
-
China’s Tigermed Taps Veeva Systems for Advanced Electronic Data Acquisition
•
Veeva Systems, a U.S.-based life science cloud software specialist, has entered into a partnership with China’s Contract Research Organization (CRO) Tigermed (SHE: 300347, HKG: 3347). This global collaboration is centered around the application of Veeva’s modern electronic data acquisition system, Vault EDC. The innovative digital solution is designed to enhance…
